Tag: Andrew Holden
Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018
Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...
Phase I/II SHIELD trial results with SB-030 in peripheral vascular disease...
Symic Bio has announced results from the phase I/II SHIELD trial evaluating SB-030, a locally administered therapeutic, in patients with peripheral vascular disease undergoing...
Andrew Holden: Nellix EVAS Global Forward Registry
Andrew Holden (Auckland City Hospital, Auckland, New Zealand) is one of the principal investigators of the Nellix EVAS FORWARD Global Registry. He explained to...
